|
1
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al Global Burden of Disease Cancer Collaboration: The
Global Burden of Cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ling CQ, Yue XQ and Ling C: Three
advantages of using traditional Chinese medicine to prevent and
treat tumor. J Integr Med. 12:331–335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Block KI, Gyllenhaal C, Lowe L, Amedei A,
Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, et
al: Designing a broad-spectrum integrative approach for cancer
prevention and treatment. Semin Cancer Biol. 35(Suppl): S276–S304.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu H, Zhao X, Liu X, Xu P, Zhang K and Lin
X: Antitumor effects of traditional Chinese medicine targeting the
cellular apoptotic pathway. Drug Des Devel Ther. 9:2735–2744.
2015.PubMed/NCBI
|
|
6
|
Wang X, Wang N, Cheung F, Lao L, Li C and
Feng Y: Chinese medicines for prevention and treatment of human
hepatocellular carcinoma: Current progress on pharmacological
actions and mechanisms. J Integr Med. 13:142–164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qu W, Wang Y, Wu Q, Liu J and Hao D:
Emodin inhibits HMGB1-induced tumor angiogenesis in human
osteosarcoma by regulating SIRT1. Int J Clin Exp Med.
8:15054–15064. 2015.PubMed/NCBI
|
|
8
|
Ma L and Li W: Emodin inhibits LOVO
colorectal cancer cell proliferation via the regulation of the
Bcl-2/Bax ratio and cytochrome c. Exp Ther Med. 8:1225–1228.
2014.PubMed/NCBI
|
|
9
|
Xie MJ, Ma YH, Miao L, Wang Y, Wang HZ,
Xing YY, Xi T and Lu YY: Emodin-provoked oxidative stress induces
apoptosis in human colon cancer HCT116 cells through a
p53-mitochondrial apoptotic pathway. Asian Pac J Cancer Prev.
15:5201–5205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yaoxian W, Hui Y, Yunyan Z, Yanqin L, Xin
G and Xiaoke W: Emodin induces apoptosis of human cervical cancer
HeLa cells via intrinsic mitochondrial and extrinsic death receptor
pathway. Cancer Cell Int. 13:712013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun ZH and Bu P: Downregulation of
phosphatase of regenerating liver-3 is involved in the inhibition
of proliferation and apoptosis induced by emodin in the SGC-7901
human gastric carcinoma cell line. Exp Ther Med. 3:1077–1081.
2012.PubMed/NCBI
|
|
12
|
Jia X, Yu F, Wang J, Iwanowycz S, Saaoud
F, Wang Y, Hu J, Wang Q and Fan D: Emodin suppresses pulmonary
metastasis of breast cancer accompanied with decreased macrophage
recruitment and M2 polarization in the lungs. Breast Cancer Res
Treat. 148:291–302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Manu KA, Shanmugam MK, Ong TH, Subramaniam
A, Siveen KS, Perumal E, Samy RP, Bist P, Lim LH, Kumar AP, et al:
Emodin suppresses migration and invasion through the modulation of
CXCR4 expression in an orthotopic model of human hepatocellular
carcinoma. PLoS One. 8:e570152013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Wang X, Zhou Q, Lu Y, Zhang H, Chen
Q, Zhao M and Su S: Inhibitory effect of emodin on migration,
invasion and metastasis of human breast cancer MDA-MB-231 cells in
vitro and in vivo. Oncol Rep. 33:338–346. 2015.
|
|
15
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei WT, Lin SZ, Liu DL and Wang ZH: The
distinct mechanisms of the antitumor activity of emodin in
different types of cancer (Review). Oncol Rep. 30:2555–2562.
2013.PubMed/NCBI
|
|
17
|
Subramaniam A, Shanmugam MK, Ong TH, Li F,
Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al:
Emodin inhibits growth and induces apoptosis in an orthotopic
hepatocellular carcinoma model by blocking activation of STAT3. Br
J Pharmacol. 170:807–821. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aroui S, Aouey B, Chtourou Y, Meunier AC,
Fetoui H and Kenani A: Naringin suppresses cell metastasis and the
expression of matrix metalloproteinases (MMP-2 and MMP-9) via the
inhibition of ERK-P38-JNK signaling pathway in human glioblastoma.
Chem Biol Interact. 244:195–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang M and Huang CZ: Mitogen-activated
protein kinase signaling pathway and invasion and metastasis of
gastric cancer. World J Gastroenterol. 21:11673–11679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang SH, Sharrocks AD and Whitmarsh AJ:
MAP kinase signalling cascades and transcriptional regulation.
Gene. 513:1–13. 2013. View Article : Google Scholar
|
|
21
|
Liu Y, Bi T, Dai W, Wang G, Qian L, Gao Q
and Shen G: Oxymatrine synergistically enhances the inhibitory
effect of 5-fluorouracil on hepatocellular carcinoma in vitro and
in vivo. Tumour Biol. Dec 18–2015.Epub ahead of print.
|
|
22
|
Chan LK, Chiu YT, Sze KM and Ng IO:
Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes
cell proliferation and migration in hepatocellular carcinoma.
Oncotarget. 6:20964–20976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao LY, Zhang J, Guo B, Yang J, Han J,
Zhao XG, Wang XF, Liu LY, Li ZF, Song TS, et al: MECP2 promotes
cell proliferation by activating ERK1/2 and inhibiting p38 activity
in human hepatocellular carcinoma HEPG2 cells. Cell Mol Biol
(Noisy-legrand). (Suppl 59): OL1876–OL1881. 2013.
|
|
24
|
Lu WJ, Chua MS and So SK: Suppression of
ATAD2 inhibits hepatocellular carcinoma progression through
activation of p53- and p38-mediated apoptotic signaling.
Oncotarget. 6:41722–41735. 2015.PubMed/NCBI
|
|
25
|
Liu B, Yuan B, Zhang L, Mu W and Wang C:
ROS/p38/p53/Puma signaling pathway is involved in emodin-induced
apoptosis of human colorectal cancer cells. Int J Clin Exp Med.
8:15413–15422. 2015.PubMed/NCBI
|
|
26
|
Liu W, Ning R, Chen RN, Huang XF, Dai QS,
Hu JH, Wang YW, Wu LL, Xiong J, Hu G, et al: Aspafilioside B
induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras
and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma
HepG2 cells. Mol Carcinog. 55:440–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Zhang J, Li X, Sun N, Yu R, Zhao
B, Yu D, Cheng Y and Liu Y: Huaier aqueous extract induces
hepatocellular carcinoma cells arrest in S phase via JNK signaling
pathway. Evid Based Complement Alternat Med. 2015:1713562015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong KK, Engelman JA and Cantley LC:
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet
Dev. 20:87–90. 2010. View Article : Google Scholar :
|
|
29
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kunter I, Erdal E, Nart D, Yilmaz F,
Karademir S, Sagol O and Atabey N: Active form of AKT controls cell
proliferation and response to apoptosis in hepatocellular
carcinoma. Oncol Rep. 31:573–580. 2014.
|
